Senior Vice President, Biotherapeutics

Ankita Srivastava has a strong track record of advancing innovative biologics and small-molecule therapeutics from early discovery through clinical development.

Before joining Tentarix, Ankita held leadership roles including VP of Antibody Engineering and Protein Sciences at AlivaMab Biologics and Ichnos Glenmark Innovation (Switzerland). She previously served as Head of Protein Sciences and Structural Biology at Denali Therapeutics, and as a Senior Scientist at Takeda Pharmaceuticals. Earlier in her career, she led Protein Sciences lab at a biotech incubator within Cedars-Sinai’s IBD department, later acquired by Prometheus Biosciences and Merck.

Ankita has built high-performing teams and developed cutting-edge capabilities to advance next-generation therapeutics—such as multi-specific antibodies, Fc-fusion proteins, and small molecules. Her efforts at Ichnos helped advance ISB 2001, a trispecific antibody for multiple myeloma, into Phase I, which later got in-licensed by AbbVie. At Denali, she contributed to the BBB penetrating Biologics platforms, foundational to DNL310 (now in late-stage trials) and DNL593/TAK-594 (in early clinical development with Takeda).

She also developed an immune repertoire display-based common light chain platform for multispecifics discovery at Alivamab that resulted in multiple business collabortions.

Ankita earned her Ph.D. in GPCR structural biology from the Max Planck Institute for Biophysics and completed postdoctoral training at Stanford University. Ankita holds an MS degree in Biotechnology and a BS degree in Chemistry and Botany from India.